Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics has secured ethics approval from the Bellberry Human Research Ethics Committee for a Phase 1 study of its NUZ-001 oral liquid formulation, marking a key milestone in the ALS drug’s development. The trial, which will enrol 32 healthy volunteers in Australia, will compare oral liquid and tablet forms under fed and fasted conditions to generate pharmacokinetic, safety and tolerability data.
The oral liquid formulation is designed to improve accessibility and continuity of treatment for ALS patients as swallowing difficulties progress, enhancing flexibility for patients, caregivers and clinicians. Study initiation is targeted for the third quarter of 2026 with completion anticipated in the fourth quarter, supporting Neurizon’s broader clinical, regulatory and commercial plans for NUZ-001 alongside its ongoing participation in the HEALEY ALS Platform Trial in the U.S.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead investigational drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis, with a strategy to accelerate patient access to effective ALS therapies while assessing broader neurodegenerative applications.
Average Trading Volume: 509,966
Technical Sentiment Signal: Sell
Current Market Cap: A$56.72M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.